What Anticoagulant Registries Are Revealing

Slides:

Advertisements

Similar presentations

The patient with atrial fibrillation who needs PCI

Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention

Covering the Bases in Cardioversion

Silent No More:.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Atrial Fibrillation and PCI

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Nat. Rev. Cardiol. doi: /nrcardio

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Real-World Safety of NOACs: What Do We Know Today?

VTE Treatment Conventional Approach

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Adherence in SPAF: Measures to Improve Care

Watching for the Patient With AF: Latest Advances and Technologies

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

NOACs in AF: Consequences of Underdosing and NonAdherence

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Cancer-Associated Thrombosis

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in Vascular Protection: From CAD to HF

NOAC Studies in VTE AF Studies Superior Outcomes.

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Program Goals Background: Anticoagulation in Patients With VTE.

NOACs in AF: Consequences of Underdosing and NonAdherence

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

Björn Redfors et al. JACEP 2017;j.jacep

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Antiarrhythmic Drugs in AF

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

What Anticoagulant Registries Are Revealing

Clinical Trials vs Registries

AFNET Registry: Cardiologist-run Centers Adhere Better to Antithrombotic Guidelines

VKA vs Dabigatran in "Real Life" (US Medicare)

Clinical Trials vs Registries

GLORIA-AF

GARFIELD

Antithrombotic Therapy in AF 2004-06 EUROHEART[a] and AFNET[b] Registry Analyses

Antithrombotic Therapy by Stroke Risk Score

Anticoagulant Use By CHA2DS2-VASc Score

GLORIA-AF Increasing Uptake of NOACs vs VKAs in Most Regions

GLORIA-AF: Increasing NOAC Uptake in Europe- Phase I versus Phase II

Real-World Studies EORP – AF pilot

NOAC Meta-analysis Stroke or SEE

Why Don't Elderly Patients Receive NOACs/VKAs?

Anticoagulant + Antiplatelet Therapy in Patients With AF at Risk for Stroke

PREFER-AF Combination Therapy (OAC and Antiplatelets) in Europe in 2012

Dabigatran and Cardioversion

New NOAC Cardioversion Trials

Summary

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)